HPR116 Expediting Reimbursement and Access for Novel Drug Indications in Europe: A Case Study on Glucagon-Like Peptide 1 (GLP-1) Agonists
Dec 1, 2024, 00:00
10.1016/j.jval.2024.10.1542
https://www.valueinhealthjournal.com/article/S1098-3015(24)04405-X/fulltext
Title :
HPR116 Expediting Reimbursement and Access for Novel Drug Indications in Europe: A Case Study on Glucagon-Like Peptide 1 (GLP-1) Agonists
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(24)04405-X&doi=10.1016/j.jval.2024.10.1542
First page :
Section Title :
Open access? :
No
Section Order :
11005